Skip to content

Study · In vitro (cells) · 2001

3 results

Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer.

Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KK

The Journal of clinical endocrinology and metabolism1 Apr 2001Cited by 91 (Europe PMC)

PMID11297608 (opens in a new tab)DOI10.1210/jcem.86.4.7403 (opens in a new tab)PepBankPUB-11297608
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In lab tests, pegylated B2036-PEG reduced membrane binding affinity by 39-fold versus unpegylated B2036.

    In plain wordsIn lab tests, B2036-PEG had lower membrane binding affinity than unpegylated B2036.

    Peptide
    Pegvisomant
    Outcome
    DecreaseMembrane receptor binding affinity
    Study

    n: not reported in source

    Comparator
    Unpegylated B2036
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pegylation substantially reduced membrane binding affinity and receptor antagonism, as assessed by a transcription assay, by 39- and 20-fold, respectively.
  2. 02LabIn vitro (cells)Activity measurement

    In lab tests, B2036-PEG reduced receptor antagonism by 20-fold versus unpegylated B2036 in a transcription assay.

    In plain wordsIn lab tests, B2036-PEG had lower receptor antagonism than unpegylated B2036.

    Peptide
    Pegvisomant
    Outcome
    DecreaseReceptor antagonism
    Study

    n: not reported in source

    Comparator
    Unpegylated B2036
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pegylation substantially reduced membrane binding affinity and receptor antagonism, as assessed by a transcription assay, by 39- and 20-fold, respectively.

Studies that did not test the peptide alone1

In this study, Pegvisomant was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pegvisomant.

  1. 03LabNot a test of Pegvisomant aloneIn vitro (cells)Activity measurement

    In lab tests, GHBP did not affect antagonism by B2036-PEG.

    In plain wordsIn lab tests, GHBP did not affect B2036-PEG antagonism compared with its absence.

    Peptide
    Pegvisomant
    Outcome
    No significant changeAntagonism with GHBP
    Study

    n: not reported in source

    Comparator
    Without GHBP
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    GHBP reduced antagonist activity of unpegylated B2036 but did not effect antagonism by B2036-PEG.

    In this study, Pegvisomant was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pegvisomant.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.